Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705013 · ClinicalTrials.gov registry record
Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)
A clinical trial, sponsored by Exact Sciences Corporation.
- Terminated
- Registry status
- 51
- Enrollment target
NCT03705013: Clinical Trial study, sponsored by Exact Sciences Corporation.
NCT03705013 is a clinical trial that was terminated before completion, run by Exact Sciences Corporation. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03705013 was terminated before completion, sponsored by Exact Sciences Corporation.
- TERMINATED
- Registry status
- 51 participants
- Enrollment target
Study Summary
The primary endpoint is to obtain longitudinal information on four sub-populations from the Cologuard Post-Approval Study.
Primary Outcome
A medical chart review and phone interview will be conducted for each subject. The Follow-Up Questionnaire will be completed during the phone interview.
Interventions
- OTHER Cologuard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2019-11-16 |
Why NCT03705013 stopped before completion
NCT03705013 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cologuard is the first listed.
NCT03705013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03705013 about?
NCT03705013 is a clinical study titled "Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)". The primary endpoint is to obtain longitudinal information on four sub-populations from the Cologuard Post-Approval Study.
What is the current status of trial NCT03705013?
This trial is currently terminated. The enrollment target is 51 participants. The study started on 2018-10-30. Estimated completion is 2019-11-16.
What interventions are being tested in trial NCT03705013?
The interventions under investigation include: Cologuard (OTHER).
Who is sponsoring clinical trial NCT03705013?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI